Partner, Domain Associates
Dr. Kim Puloma Kamdar is a Partner at Domain Associates, a Healthcare focused Venture Capital Firm.
Kim is currently Chairman of the Board of Directors of Obalon (NASDAQ: OBLN) and Truvian Sciences. She also serves on the BOARD of Epic Sciences, EvoFem Sciences, Omniome, ROX Medical, and Sera Prognostics, She was formerly a board member of Syndax Pharmaceuticals (NASDAQ: SNDX) and Tragara Pharmaceuticals. Kim was also involved with Ariosa Diagnostics until the company was sold to Roche in January 2015, Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to sanofi-aventis in April 2009.
Prior to Domain, Kim was a Kauffman Fellow and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.
Kim serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine. She is also a board member of Access Youth Academy, which hopes to transform the lives of underserved youth through academic mentorship and urban squash.